沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床疗效

doi:10.3969/j.issn.1671-7171.2025.06.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1254 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床效果。【方法】选择2019年2月至2023年3月两院收治的98例高血压合并慢性心力衰竭患者,采用随机数字表法将所有患者分为观察组和对照组,每组49例。比较两组患者治疗前后血压,血清N-末端脑钠肽前体(NT-proBNP)、血管紧张素Ⅱ(AngⅡ)水平,心功能指标[左心室收缩末内径(LVESD)、左心室舒张末内径(LVEDD)、左室射血分数(LVEF)]及用药安全性。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组收缩压、舒张压均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组血清NT-proBNP、AngⅡ水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组LVESD、LVEDD低于治疗前,LVEF高于治疗前(P<0.05),且观察组LVESD、LVEDD均低于对照组,LVEF高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】沙库巴曲缬沙坦可降低高血压合并慢性心力衰竭患者血清AngⅡ、NT-proBNP水平,降低血压,改善心功能,且安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	万钧
	王文远

关键词 ：高血压, 心力衰竭, 慢性病, 缬沙坦, 治疗结果

Abstract：【Objective】To investigate the clinical efficacy of sacubitril valsartan in the treatment of hypertension with chronic heart failure. 【Methods】A total of 98 patients with hypertension and chronic heart failure admitted to the two hospitals from February 2019 to March 2023 were selected. The patients were randomly divided into the observation group and the control group using a random number table, with 49 patients in each group. Blood pressure, serum N-terminal pro brain natriuretic peptide (NT-proBNP), angiotensin Ⅱ (Ang Ⅱ) levels, cardiac function indicators [left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)], and medication safety were compared between two groups before and after treatment. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the systolic and diastolic blood pressure in both groups were lower than those before treatment, and the value of the observation group was lower than that of the control group, with a statistically significant difference (P<0.05). The serum levels of NT-proBNP and AngⅡ in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group with statistically significant difference (P<0.05). LVESD and LVEDD after treatment in both groups were lower than those before treatment, while LVEF was higher than that before treatment (P<0.05). After treatment, both LVESD and LVEDD of the observation group were lower than those of the control group, while LVEF was higher than that of the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Sacubitril valsartan can reduce the levels of serum AngⅡ and NT-proBNP in patients with hypertension and chronic heart failure, lower blood pressure, improve cardiac function. And it is safe and reliable.

Key words： Hypertension Heart Failure Chronic Disease Valsartan Treatment Outcome

收稿日期: 2024-12-10

中图分类号:

R542.22

引用本文:

万钧, 王文远. 沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床疗效[J]. 医学临床研究, 2025, 42(6): 1007-1010.
WAN Jun, WANG Wenyuan. Clinical Effect of Shakubactri Valsartan in the Treatment of Chronic Heart Failure with Hypertension. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 1007-1010.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.06.027 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I6/1007

[1] SLIVNICK J, LAMPERT B C.Hypertension and heart failure[J].Heart Fail Clin,2019,15(4):531-541.
[2] 唐彪,傅慎文. 贝那普利与美托洛尔联合治疗对老年原发性高血压合并慢性心力衰竭患者心功能指标、昼夜节律变化及心率变异性的影响[J].中国医师杂志,2020,22(9):1413-1416.
[3] DOCHERTY K F, VADUGANATHAN M, SOLOMON S D, et al.Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF[J].JACC Heart Fail,2020,8(10):800-810.
[4] HEYSE A, MANHAEGHE L, MAHIEU E, et al.Sacubitril/valsartan in heart failure and end-stage renal insufficiency[J].ESC Heart Fail,2019,6(6):1331-1333.
[5] 中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南( 2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122.
[7] BREDY C, MINISTERI M, KEMPNY A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome[J].Eur Heart J Qual Care Clin Outcomes,2018,4(1):51-58.
[8] 王清传,张志敏,李喆,等. 血浆可溶性生长刺激表达基因2蛋白水平对门诊心力衰竭患者预后的影响[J].海军医学杂志,2020,41(5):561-563.
[9] SORRENTINO M J.The Evolution from hypertension to heart failure[J].Heart Fail Clin,2019 ,15(4):447-453.
[10] BORLAUG B A.Evaluation and management of heart failure with preserved ejection fraction[J].Nat Rev Cardiol,2020,17(9):559-573.
[11] 赵金艳,崔少楠,曹月娟. 沙库巴曲缬沙坦钠治疗老年高血压慢性心力衰竭的疗效观察[J].中华老年心脑血管病杂志,2021,23(12):1268-1271.
[12] SCHMITT W, RÜHS, BURGHAUS R, et al.NT-proBNP qualifies as a surrogate for clinical end points in heart failure[J].Clin Pharmacol Ther,2021,110(2):498-507.
[13] SON Y J, CHOI J, LEE H J.Effectiveness of nurse-led heart failure self-care education on health outcomes of heart failure patients: a systematic review and meta-analysis[J].Int J Environ Res Public Health,2020,17(18):6559.
[14] 黄婕,韦方练,李丹,等. 高血压合并慢性心力衰竭患者血清AngⅡ、ALD、NT-pro-BNP水平及与预后的相关性研究[J].国际检验医学杂志,2021,42(15):1797-1801.
[15] 贾红丹,丛洪良,赵云凤,等. 沙库巴曲缬沙坦治疗慢性心力衰竭患者的疗效观察[J].天津医药,2019,47(10):1076-1080.
[16] 张小红,李俭强,李天开,等. 沙库巴曲缬沙坦对急性失代偿性心力衰竭患者短期预后的改善作用[J].临床内科杂志,2022,39(10):671-674.
[17] 何云,李小红,张燕,等. 沙库巴曲缬沙坦治疗急性失代偿射血分数降低心力衰竭患者的有效性和安全性[J].西部医学,2022,34(11):1673-1678.